News

Biodesix Strengthens Partnership with Bio-Rad for Advanced Testing

Biodesix Strengthens Partnership with Bio-Rad for Advanced Testing

Partnership Expansion Between Biodesix and Bio-Rad

Biodesix, Inc. (NYSE: BDSX), a prominent diagnostics solutions company, has recently strengthened its collaboration with Bio-Rad Laboratories. This expanded partnership focuses on developing and validating advanced in vitro diagnostic assays aimed at enhancing the detection of genomic markers in oncology applications. Utilizing Bio-Rad's renowned Droplet Digital™ PCR technology on its QX600 platform, Biodesix aims to create highly sensitive assays tailored for precise cancer diagnostics.

Cutting-Edge Assays for Oncology Applications

The initial assay being worked on under this partnership is the ddPLEX ESR1 Mutation Detection Assay. This assay holds significant potential as ESR1 testing is critical for managing HR+/HER2- advanced breast cancer. The technologies being utilized will allow for accurate detection and quantification of various ESR1 mutations within circulating tumor DNA (ctDNA) samples, which is vital for improving patient outcomes.

Supporting Biopharma and Clinical Clients

Once the validation process is complete, the ESR1 mutation assay will be available as a test service at Biodesix' accredited laboratory, which is CLIA-CAP certified. This offering aims to support biopharmaceutical companies in developing targeted therapies and assist clinical practitioners in monitoring cancer treatments effectively. Moreover, Biodesix plans to work closely with the Centers for Medicare & Medicaid Services (CMS) to explore reimbursement options for the assay, emphasizing its commitment to accessible healthcare innovations.

Leadership Insights on the Partnership

Scott Hutton, the CEO of Biodesix, expressed enthusiasm regarding the expanded partnership. "The emergence of ESR1 mutations as significant biomarkers has transformed the landscape of breast cancer treatment. We are eager to enhance our capabilities through this collaboration, ensuring rapid and sensitive assay development that meets clinical demands and paves the way for personalized medicine," he stated.

Ongoing Collaboration in the Oncology Field

Steve Kulisch, VP of Product Management at Bio-Rad Laboratories, commented on the long-standing relationship with Biodesix. He noted that their previous collaborations have effectively addressed both clinical and research applications, particularly in non-small cell lung cancer diagnostics. The advancement of the ddPLEX ESR1 kits represents another step forward in their mission to improve biomarker detection and patient outcomes for advanced breast cancer.

Upcoming Events and Presentations

Biodesix and Bio-Rad will be featuring their collaborative efforts and R&D visions at an upcoming conference. They will detail their partnership at the AMP conference, scheduled for mid-November in Boston, MA. This event will provide insights into their commercial strategies and future developments in clinical research.

About Biodesix

Biodesix is devoted to advancing diagnostic solutions that enhance patient care and clinical outcomes. Their products, such as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, are designed to assist healthcare providers in making informed decisions quickly. Furthermore, Biodesix Development Services empower top biopharmaceutical and life sciences organizations by providing essential support for developing innovative diagnostic tools and therapeutic solutions.

Contact Information for Biodesix

Media Inquiries:
Natalie St. Denis, Director of Corporate Communications
Email: natalie.stdenis@biodesix.com
Phone: (720) 925-9285

Investor Relations:
Chris Brinzey, Partner at ICR
Email: chris.brinzey@icrhealthcare.com
Phone: (339) 970-2843

Frequently Asked Questions

What is the focus of the partnership between Biodesix and Bio-Rad?

The partnership focuses on developing advanced diagnostic assays for oncology applications using Bio-Rad's ddPCR technology.

What is the significance of the ESR1 Mutation Detection Assay?

This assay is crucial for detecting mutations in HR+/HER2- advanced breast cancer, thereby aiding in patient treatment management.

How will the ESR1 assay benefit biopharma clients?

It will support biopharma clients in developing targeted therapies and monitoring treatment effectiveness.

What are the future plans for Biodesix regarding the ESR1 assay?

Biodesix plans to validate the assay and seek reimbursement options through CMS to ensure accessibility for patients.

What are Biodesix's main products?

Biodesix offers Nodify Lung for nodule risk assessment and IQLung for cancer treatment guidance, improving decision-making in clinical settings.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Haier Biomedical's Strategic Expansion in the U.S.

Updated Category News Views 23

Nailing the U.S. Market with Cold Precision Haier Biomedical isn't just in the game to compete—they're setting the game rules with their mind-boggling expertise in blood management and pharmaceutical storage solutions. This October, they took center stage at the AABB and ISPE 2026 meetings, and they weren't messing around. Fresh Off the Exhibit Floor: Haier's Ambitions...

Continue Reading
Collective Scoops $100M, Powers Solopreneur's Financial Might

Updated Category News Views 0

Picture This: A Solo Businessman in 2026 Imagine a lone ranger running a show that used to take an entire office. That’s the magic happening with roughly 30 million solo businesses in the U.S. today, and folks, the numbers are staggering. As these one-man-bands push past clunky old systems, a big name is lighting the way: Collective. They raised a hefty $100 million to...

Continue Reading
Shield HealthCare Expands Access for Astiva Members

Updated Category News Views 46

Opening Up New Avenues for Health Care Here's a nugget from the healthcare sector that's worth chewing on. Shield HealthCare has just inked a deal with Astiva Health that opens the floodgates for eligible members in Southern California to access medical supplies through Shield's extensive network. It's a big move that aims to make health management a tad easier for folks...

Continue Reading
Luxury Travel Spikes While Budget Trips Take a Hit

Updated Category News Views 73

Luxury Trips on The Uptrend Luxury travel is surging while budget trips are taking a backseat. According to Squaremouth's latest data, high-end getaways insured for a whopping $30,000 or more shot up by 27.2% in the third quarter of 2026 compared to the same time last year. In contrast, budget-friendly jaunts under $10,000 dipped by 2.3%. Travelers seem ready to splurge...

Continue Reading
Hershey's Sweet Results: 2026 Earnings Soar

Updated Category News Views 94

Hershey's 2026 Q3 Financial Performance: A Closer Look At the end of September, The Hershey Company (NYSE: HSY) dished out some eye-popping numbers for their third quarter. With a net sales increase of 3.0%, they clocked in at $3,275.5 million. More importantly, earnings per share-diluted shot up by a whopping 111.8%, landing at $2.88. Clearly, Hershey’s strategic moves...

Continue Reading
BTQ's MIMIQ: A Quantum Leap for 35,000 Developers

Updated Category News Views 24

Breaking Barriers in Quantum Emulation If you think the quantum computing game is all about hardware, then you're missing half the picture. Enter BTQ Technologies, crash-landing into the scene by throwing open the doors of their MIMIQ emulator to a crowd of over 35,000 quantum developers through qBraid. This ain't just an upgrade—it's a seismic shift. More qubits, more...

Continue Reading
HiTHIUM Powers Up Australia's Energy Storage Future

Updated Category News Views 92

Just imagine, folks, a slice of the energy world reshaping right under our feet in good ol' Australia. That's the buzz HiTHIUM sparked at All Energy Australia as they showcased their fancy ?Power 6.9MWh, 8-hour long-duration battery storage system (BESS). It wasn’t just about the tech superiority but the strategic planting of stakes in the local energy market....

Continue Reading
XREAL AURA: A New Era of Wired XR Glasses

Updated Category News Views 72

Pioneering the XR Frontier Welcome to another day under the sun of cutting-edge tech, where XREAL's striking a chord with its new wired XR glasses—AURA. First off, don't let the tangled history of tech hype get to you. In the wild world of extended reality, we've seen plenty of flash, not enough substance. But XREAL's hitting the market with AURA, and I gotta say,...

Continue Reading
Solink Secures $100M: NYSE Sees Tech and Sports Moves

Updated Category News Views 64

Folks, it’s a busy day on Wall Street, with Solink leading the charge by landing over a cool $100 million in fresh funding. Let's break this down because when startups pocket nine-digit figures, it's time to pay attention. Solink's Leap Forward Now, what’s Solink doing with all that cash? They're not scrambling for coffee money, that's for sure. Instead, this funding...

Continue Reading
Circus Circus Vegas Offers Halloween Deals for Families

Updated Category News Views 0

Halloween at Circus Circus: A New Spin on Family Fun Ah, Circus Circus Las Vegas. It's that place that’s managed to blend screaming kids, excited parents, and a flurry of flashing lights into something resembling an amusement park—on the Strip no less. Now, they're turning up the heat for Halloween. Yup, they're rolling out half-price Midway games and Adventuredome...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Soaring Growth of the Graphene Market Ahead

Updated Category News Views 264

Understanding the Growth of the Graphene Market The Graphene market is witnessing a remarkable journey, with projections suggesting it could reach an astounding USD 4,997.1 million by 2032. This growth represents a captivating compound annual growth rate (CAGR) of 33.2% from 2024 to 2032, highlighting the material's increasing application across diverse sectors such as...

Continue Reading
Volvo Group Navigates Q3 Market Challenges and Future Prospects

Updated Category News Views 124

Volvo Group's Third Quarter Summary Volvo Group (OTC: VLVLY, VOLV.B) has reported a challenging third quarter for 2024, characterized by normalization of demand in key segments. The company experienced a decline in net sales, recording SEK 170 billion, while adjusted operating income stood at SEK 14.1 billion with a 12% margin. These figures reflect the ongoing...

Continue Reading
Exploring the Future of Digital Security Control: A Growth Story

Updated Category News Views 337

Digital Security Control Market Overview The Digital Security Control Market is witnessing transformative growth, fueled by increasing cyber threats and the rising demand for sophisticated security solutions. By integrating technologies like artificial intelligence and machine learning, organizations are rethinking their approach to cybersecurity, adapting to the evolving...

Continue Reading
Carisma Therapeutics Set to Share Innovations at Key Conference

Updated Category News Views 127

Carisma Therapeutics to Share Insights at Annual Conference Carisma Therapeutics Inc. (NASDAQ: CARM), known for its innovative macrophage-focused therapies, is gearing up to make waves at an upcoming virtual event. This conference will allow the company to highlight its advancements in developing therapies aimed at combating significant health issues, including cancer and...

Continue Reading
XWELL, Inc.: Strong Third Quarter Performance and Future Outlook

Updated Category News Views 72

Overview of XWELL, Inc.'s Performance XWELL, Inc. (Nasdaq: XWEL), known for its innovative wellness solutions, has shown significant progress in its recent reports. The company has experienced a remarkable revenue growth of around 13% for the third quarter, compared to the same period last year. This uptick reflects a robust strategy towards sustainable profit recovery...

Continue Reading